Skip to Main Content

Paper Details

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.
Clin Cancer Res
31
2021
Author NameAffiliation
David SchiffUniversity of Virginia
Ghazaleh TabatabaiUniversity Hospital of Tubingen, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology at Comprehensive Cancer Center Tubingen, Eberhard Karls University Tubingen
  • 1 - 2

Datasets

Release 1.2